It turns out that chronic ISR activation and resulting blockage of cellular protein production may play a role in a surprisingly wide array of neurological conditions. Below is a partial list of these conditions, based on a recent review by Walter and colleague Mauro Costa-Mattioli of Baylor College of Medicine, which could potentially be treated with an ISR-resetting agent like ISRIB:
This small molecule was discovered in 2013 by Walter so it's been around a few years. Evidently the brain hacker community is interested in it, so there may be some first-hand accounts from people that actually used it. Conversation on Reddit discusses how it might be used to restore a brain damaged by concussion.Two things I've learned so far: it works differently than many other medicines in that it's supposed to unstick something in the brain that gets stuck in a survival mode rather than a repair mode. In other words, this would be something you would take for a short time just to unstick your brain so that it can get out of survival mode and perform normally again. Which is good, because I also discovered this stuff is very very expensive if you can get it at all. Which of course I would not recommend until we can get it as a prescription from our doctors.
One other tidbit I discovered is that the very well-funded and talented company called Calico, which is owned by Alphabet (which also owns Google) recently purchased a license to study this molecule. Hopefully their well funded researchers will find whatever there is to find and market it.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
READ this ENCOURAGING study on Vielight and Photobiomodulation (PMB)!
Diet and auto immune disease.
Research finds Taurine to be neuroprotective in a Parkinson's disease mouse model 
Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD
